Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6JCya-Flt3em1/Cya
Common Name:
Flt3-KO
Product ID:
S-KO-02085
Background:
C57BL/6JCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Flt3-KO
Strain ID
KOCMP-14255-Flt3-B6J-VB
Gene Name
Flt3
Product ID
S-KO-02085
Gene Alias
B230315G04; CD135; Flk-2; Flk2; Flt-3; Ly72; wmfl
Background
C57BL/6JCya
NCBI ID
14255
Modification
Conventional knockout
Chromosome
5
Phenotype
MGI:95559
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6JCya-Flt3em1/Cya mice (Catalog S-KO-02085) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000049324
NCBI RefSeq
NM_010229
Target Region
Exon 3
Size of Effective Region
~1.0 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Flt3, also known as FMS-like tyrosine kinase 3, is a receptor tyrosine kinase almost exclusively expressed in the hematopoietic compartment. Its ligand, FLT3 ligand (FL), induces dimerization and activation of its intrinsic tyrosine kinase activity. Activation of Flt3 leads to autophosphorylation and initiation of signal transduction cascades like STAT5, MAPK and AKT, mediating cell survival, proliferation, and differentiation of hematopoietic progenitor cells [4,5].

Mutations in the Flt3 gene are the most frequent genetic alteration in acute myeloid leukemia (AML), occurring in approximately 30% of all AML cases. The two major types are internal tandem duplication (ITD) in the juxtamembrane domain and point mutations or deletions in the tyrosine kinase domain (TKD). Flt3-ITD is the most common, present in about 25% of AML cases, associated with high leukemic burden, increased relapse, and poor prognosis. Flt3-TKD has a lower incidence (about 7-10% of cases), and its prognostic value is uncertain. Clonal evolution of Flt3 mutational status occurs during the disease. First-generation Flt3 inhibitors are broad-spectrum, while next-generation ones are more specific, but resistance to these inhibitors remains a challenge [1,2,3,4,7,8].

In conclusion, Flt3 is crucial for normal hematopoietic cell function through its signaling pathways. In AML, Flt3 mutations, especially Flt3-ITD, play a significant role in disease progression and prognosis. Understanding Flt3 through genetic models could potentially lead to better targeted therapies for AML patients. The development and use of Flt3 inhibitors, despite the resistance challenges, have already changed the treatment landscape for Flt3-mutated AML [1,2,3,4,6,7,8].

References:

1. Daver, Naval, Schlenk, Richard F, Russell, Nigel H, Levis, Mark J. 2019. Targeting FLT3 mutations in AML: review of current knowledge and evidence. In Leukemia, 33, 299-312. doi:10.1038/s41375-018-0357-9. https://pubmed.ncbi.nlm.nih.gov/30651634/

2. Kennedy, Vanessa E, Smith, Catherine C. 2020. FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies. In Frontiers in oncology, 10, 612880. doi:10.3389/fonc.2020.612880. https://pubmed.ncbi.nlm.nih.gov/33425766/

3. Negotei, Cristina, Colita, Andrei, Mitu, Iuliana, Stanca, Oana, Berbec, Nicoleta Mariana. 2023. A Review of FLT3 Kinase Inhibitors in AML. In Journal of clinical medicine, 12, . doi:10.3390/jcm12206429. https://pubmed.ncbi.nlm.nih.gov/37892567/

4. Kiyoi, Hitoshi, Kawashima, Naomi, Ishikawa, Yuichi. 2019. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. In Cancer science, 111, 312-322. doi:10.1111/cas.14274. https://pubmed.ncbi.nlm.nih.gov/31821677/

5. Kazi, Julhash U, Rönnstrand, Lars. . FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications. In Physiological reviews, 99, 1433-1466. doi:10.1152/physrev.00029.2018. https://pubmed.ncbi.nlm.nih.gov/31066629/

6. Bystrom, Rebecca, Levis, Mark J. 2023. An Update on FLT3 in Acute Myeloid Leukemia: Pathophysiology and Therapeutic Landscape. In Current oncology reports, 25, 369-378. doi:10.1007/s11912-023-01389-2. https://pubmed.ncbi.nlm.nih.gov/36808557/

7. Arai, Yasuyuki, Chi, SungGi, Minami, Yosuke, Yanada, Masamitsu. 2022. FLT3-targeted treatment for acute myeloid leukemia. In International journal of hematology, 116, 351-363. doi:10.1007/s12185-022-03374-0. https://pubmed.ncbi.nlm.nih.gov/35532877/

8. Fedorov, Kateryna, Maiti, Abhishek, Konopleva, Marina. 2023. Targeting FLT3 Mutation in Acute Myeloid Leukemia: Current Strategies and Future Directions. In Cancers, 15, . doi:10.3390/cancers15082312. https://pubmed.ncbi.nlm.nih.gov/37190240/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest